Q2 2025 QuidelOrtho Corp Earnings Call Transcript
Key Points
- QuidelOrtho Corp (QDEL) reported a 1% revenue growth excluding COVID and Donor Screening, with strong performance in Labs and Immunohematology business units.
- The company achieved a 330 basis point improvement in adjusted EBITDA margin, reflecting successful cost structure actions.
- QuidelOrtho Corp (QDEL) saw significant growth in international markets, with Latin America, Japan, Asia Pacific, and EMEA regions showing strong performance.
- The company is optimistic about its molecular strategy, particularly the acquisition of LEX Diagnostics, which is expected to enhance its growth potential.
- QuidelOrtho Corp (QDEL) earned first place rankings by ServiceTrac for best overall clinical chemistry and integrated system performance, highlighting its customer-focused approach.
- North America revenue declined by 12% during the quarter, attributed to seasonally low viral prevalence.
- COVID-related revenue decreased significantly, impacting overall revenue figures and leading to a revised full-year COVID revenue guidance.
- The company is facing potential tariff headwinds estimated at $20 million to $25 million for 2025, although this is lower than previous estimates.
- The Donor Screening business is being wound down, contributing to a decrease in total revenue.
- QuidelOrtho Corp (QDEL) experienced a decrease in Point of Care revenue by 21%, primarily due to lower COVID sales.
Welcome to the QuidelOrtho second-quarter 2025 financial results conference call and broadcast. (Operator Instructions) Please note, this conference call is being recorded. An audio replay of this conference call will be available on the company's webcast shortly after this call.
I would now like to turn the call over to Juliet Cunningham, the Vice President of Investor Relations. Please proceed.
Thank you. Good afternoon, everyone, and thanks for joining the QuidelOrtho second-quarter 2025 financial results conference call. Joining me today are Brian Blaser, President and Chief Executive Officer; and Joe Busky, Chief Financial Officer. This conference call is being simultaneously webcast on the Investor Relations page of our website. To aid in the presentation, we have also posted supplemental information on the Investor Relations page that will be referenced throughout this call.
This conference call and supplemental information contain forward-looking statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
